Super P‑Force Oral Jelly combines sildenafil (100 mg)—a phosphodiesterase‑5 inhibitor—and dapoxetine (60 mg), used for erectile dysfunction and premature ejaculation respectively. Sildenafil, the active Super P-Force Oral Jelly drug in Revatio, is indeed approved to treat pulmonary arterial hypertension (PAH). In PAH, it works by relaxing pulmonary arteries, improving exercise capacity and hemodynamics.
However, Revatio (brand-name sildenafil for PAH) is specifically dosed differently—typically 20 mg three times daily, up to 80 mg TID—and comes in tablets or oral suspension designed for PAH. Clinical studies have shown significant improvements in walking distance, pulmonary artery pressure, and functional class at these doses.
In contrast, Super P‑Force Oral Jelly delivers a much higher single dose (100 mg) intended for sexual activity, not the consistent, controlled dosing regimen required for treating PAH. That high, intermittent dose—combined with dapoxetine—has not been studied or approved for PAH.
Add your comment